205 related articles for article (PubMed ID: 9074944)
1. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis.
Taniguchi H; Yomota E; Kume E; Shikano T; Endo T; Nagasaki M
Jpn J Pharmacol; 1997 Feb; 73(2):105-12. PubMed ID: 9074944
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
Taniguchi H; Yazaki N; Yomota E; Shikano T; Endo T; Nagasaki M
Eur J Pharmacol; 1996 Sep; 312(2):227-33. PubMed ID: 8894600
[TBL] [Abstract][Full Text] [Related]
3. Effects of loxiglumide on experimental acute pancreatitis in comparison with gabexate mesilate.
Kimura K; Tominaga K; Fujii M; Saito T; Kasai H
Arzneimittelforschung; 1998 Jan; 48(1):65-9. PubMed ID: 9522035
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro.
Taniguchi H; Yazaki N; Endo T; Nagasaki M
Eur J Pharmacol; 1996 May; 304(1-3):147-54. PubMed ID: 8813597
[TBL] [Abstract][Full Text] [Related]
5. CCK administration after CCK receptor blockade accelerates recovery from cerulein-induced acute pancreatitis in rats.
Nakano S; Kihara Y; Otsuki M
Pancreas; 1998 Mar; 16(2):169-75. PubMed ID: 9510141
[TBL] [Abstract][Full Text] [Related]
6. Camostate- and caerulein-induced delay of gastric emptying in the rat: effect of CCK receptor antagonists.
Varga G; Scarpignato C
Eur J Pharmacol; 1996 Jun; 306(1-3):153-9. PubMed ID: 8813627
[TBL] [Abstract][Full Text] [Related]
7. Effect of a new CCK-A receptor antagonist, dexloxiglumide, on the exocrine pancreas in the rat.
Varga G; Kisfalvi K; D'Amato M; Scarpignato C
J Physiol Paris; 1997; 91(3-5):257-64. PubMed ID: 9403804
[TBL] [Abstract][Full Text] [Related]
8. [Effect of KSG-504, a new CCK-A-receptor antagonist, on experimental acute pancreatitis in rats and mice].
Kobayashi M; Shinagawa K; Sugiura M; Nagasawa T; Akahane M; Ajisawa Y
Nihon Yakurigaku Zasshi; 1996 Apr; 107(4):183-95. PubMed ID: 8690301
[TBL] [Abstract][Full Text] [Related]
9. Effect of a new cholecystokinin receptor antagonist CR 1392 on caerulein-induced acute pancreatitis in rats.
Otsuki M; Tani S; Okabayshi Y; Nakamura T; Fujii M; Fujisawa T; Baba S; Itoh H
Pancreas; 1989; 4(2):237-43. PubMed ID: 2474165
[TBL] [Abstract][Full Text] [Related]
10. Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice.
Niederau C; Liddle RA; Williams JA; Grendell JH
Gut; 1987; 28 Suppl(Suppl):63-9. PubMed ID: 2446964
[TBL] [Abstract][Full Text] [Related]
11. Oral administration of sepimostat mesilate prevents acute alcohol pancreatic injury in rats.
Yuasa C; Irimura K; Oda M; Fukui K; Oka T
J Pharm Pharmacol; 1999 Jul; 51(7):867-71. PubMed ID: 10467964
[TBL] [Abstract][Full Text] [Related]
12. Acceleration of ulcer healing by cholecystokinin (CCK): role of CCK-A receptors, somatostatin, nitric oxide and sensory nerves.
Brzozowski T; Konturek PC; Konturek SJ; Pajdo R; Drozdowicz D; Kwiecień S; Hahn EG
Regul Pept; 1999 Jun; 82(1-3):19-33. PubMed ID: 10458643
[TBL] [Abstract][Full Text] [Related]
13. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas.
Dembinski A; Jaworek J; Konturek PK; Konturek SJ; Warzecha Z
J Physiol; 1989 Apr; 411():419-35. PubMed ID: 2614728
[TBL] [Abstract][Full Text] [Related]
14. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
Nakano S; Tachibana I; Otsuki M
Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
[TBL] [Abstract][Full Text] [Related]
15. Lack of effect of cholecystokinin receptor antagonist (CR1505) on recovery of experimental pancreatitis after pancreatic duct occlusion in rats.
Tomita H; Miyasaka K; Jimi A; Mishima Y; Funakoshi A
Pancreas; 1994 Sep; 9(5):638-45. PubMed ID: 7809019
[TBL] [Abstract][Full Text] [Related]
16. Effect of a new cholecystokinin receptor antagonist loxiglumide on acute pancreatitis in two experimental animal models.
Tani S; Okabayashi Y; Nakamura T; Fujii M; Itoh H; Otsuki M
Pancreas; 1990 May; 5(3):284-90. PubMed ID: 2343042
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
Ito H; Sogabe H; Nakarai T; Sato Y; Tomoi M; Kadowaki M; Matsuo M; Tokoro K; Yoshida K
J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
[TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
Shiratori K; Takeuchi T; Satake K; Matsuno S;
Pancreas; 2002 Jul; 25(1):e1-5. PubMed ID: 12131781
[TBL] [Abstract][Full Text] [Related]
19. Early development of experimental biliary pancreatitis and its amelioration by CCK-receptor blockade.
Niederau C; Borchard F; Lüthen R; Niederau M
Hepatogastroenterology; 1996; 43(12):1442-53. PubMed ID: 8975946
[TBL] [Abstract][Full Text] [Related]
20. Beneficial effects of the synthetic trypsin inhibitor camostate in cerulein-induced acute pancreatitis in rats.
Otsuki M; Tani S; Okabayashi Y; Fuji M; Nakamura T; Fujisawa T; Itoh H
Dig Dis Sci; 1990 Feb; 35(2):242-50. PubMed ID: 1689237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
